CytoSorbents Corporation (CTSO)

[andy55q]

All patients experienced cytokine release syndrome (CRS). Of the 30 patients, 74% (n=22) experienced mild to moderate CRS. Severe CRS, seen in 27% of patients (n=8), was associated with higher disease burden and effectively treated with the IL-6 receptor antibody tocilizumab. Several patients experienced neurologic toxicities, which fully resolved without further intervention or apparent long-term implications[1].

October 15, 2014 23:00 CET
Novartis announces CTL019 data published in NEJM demonstrating efficacy in certain patients with acute lymphoblastic leukemia (ALL)
Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL019[1]
Largest published cohort to date for CTL019, which served as the basis for recent Breakthrough Therapy designation from the FDA[2]
Sustained remissions of up to two years in r/r ALL patients with six-month event-free survival of 67% and overall survival of 78%[1]
Novartis and Penn have exclusive global collaboration to research, develop and commercialize CAR T cell therapies for the investigational treatment of cancers
http://www.novartis.com/newsroom/media-releases/en/2014/1863311.shtml